ClinicalTrials.gg
TerminatedNCT04060147Updated Jul 27, 2023Results posted

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

A Phase 1 interventional study of Cilofexor in Primary Sclerosing Cholangitis and Compensated Cirrhosis, sponsored by Gilead Sciences. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Why this study was terminated
The study enrollment was terminated early by the sponsor due to recruitment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
44th of 57
11 · median 27
Started
2019
with 4 others
Phase 1
19 of 75
5 open now
Registered
51st of 75
by date
Lead sponsor
7 of 75
Gilead Sciences

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 44th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2019, is one of 19 in phase 1, and was the 51st registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

03

Conditions studied

  • Primary Sclerosing Cholangitis
  • Compensated Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis PSC based on cholangiogram (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], or percutaneous transhepatic cholangiogram [PTC]) or liver
  • Individuals have evidence of cirrhosis based on historical liver biopsy, abdominal imaging [magnetic resonance imaging (MRI), computed tomography (CT), or Ultrasound], or a screening FibroScan®, enhanced liver fibrosis (ELF)™, or FibroTest®.
  • Individual has the following laboratory parameters at the Screening visit, as determined by the central laboratory:

    • Estimated (eGFR) > 60 milliliter/minute (mL/min), as calculated by the equation
    • (ALT) ≤ 5 x (ULN)
    • Total 2 milligram/deciliter (mg/dL), unless the individual is known to have Gilbert's syndrome or hemolytic anemia
    • (INR) ≤ 1.4, unless due to therapeutic anticoagulation
    • count ≥ 75,000/microliter (μL). Individuals with evidence of high-risk esophageal or gastric varices in the opinion of the investigator are excluded
    • Negative anti-mitochondrial antibody

Key Exclusion Criteria:

  • Current or prior history of any of the following

    • Decompensated liver disease, including ascites, hepatic encephalopathy (HE), or variceal hemorrhage
    • Liver transplantation
    • Cholangiocarcinoma or hepatocellular carcinoma (HCC).
  • Model for End-stage Liver Disease (MELD) score > 12 at Screening, unless due to an alternate etiology such as therapeutic anticoagulation
  • (CP) score > 6 at Screening, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation
  • Current moderate to severely active inflammatory bowel disease (IBD) (including ulcerative colitis, Crohn's disease, and indeterminate colitis).

    • Note: Individuals with IBD who currently have an external ostomy bag and/or proctocolectomy are not subject to this exclusion criterion and need not undergo IBD Symptom Severity Assessment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Cilofexor

    Participants will receive escalating doses of cilofexor 30 mg, 60 mg, and 100 mg.

    Drug: Cilofexor

Interventions

  • Tablets administered orally once daily

    Also known as: CILO, GS-9674

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events (TEAEs) were either defined any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to 12 weeks plus 30 days

  2. Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)

    A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death ; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs.

    Time frame: First dose date up to 12 weeks plus 30 days

  3. Percentage of Participants Who Experienced Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening.

    Time frame: First dose date up to 12 weeks plus 30 days

07

Results

Posted Jul 27, 2023

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneCilofexor
Started11
Completed10
Not completed1
Withdrew: Withdrew consent1

Outcome measures

PrimaryPercentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

Treatment-emergent adverse events (TEAEs) were either defined any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to 12 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
percentage of participantsCilofexor
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)81.8
PrimaryPercentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)

A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death ; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs.

Time frame:
First dose date up to 12 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)
percentage of participantsCilofexor
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)0
PrimaryPercentage of Participants Who Experienced Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening.

Time frame:
First dose date up to 12 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Laboratory Abnormalities
percentage of participantsCilofexor
Grade 154.5
Grade 236.4
Grade 39.1
Grade 40

Adverse events

Collected over All-Cause Mortality: Enrollment up to 17 weeks; Adverse Events: First dose date up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cilofexor0/11 (0%)0/11 (0%)9/11 (81.8%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCilofexor
PruritusSkin and subcutaneous tissue disorders8/11
NauseaGastrointestinal disorders2/11
FatigueGeneral disorders2/11
Upper respiratory tract infectionInfections and infestations2/11
HeadacheNervous system disorders2/11
VertigoEar and labyrinth disorders1/11
ConstipationGastrointestinal disorders1/11
Defaecation urgencyGastrointestinal disorders1/11
DiarrhoeaGastrointestinal disorders1/11
Ill-defined disorderGeneral disorders1/11

Baseline characteristics

Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cilofexor
Mean49 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Cilofexor
Female5
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor
Race — Black or African American1
Race — White10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor
Ethnicity — Not Hispanic or Latino10
Ethnicity — Hispanic or Latino1
Region of Enrollment
Region of Enrollment(Participants)Cilofexor
United States11
08

Study locations

16 sites
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • University of California San Francisco, Liver Clinic
    San Francisco, California 94143, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Minnesota Gastroenterology, PA
    Maplewood, Minnesota 55117, United States
  • Northwell Health Center for Liver Diseases and Transplantation
    Manhasset, New York 11030, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • University of Virginia Medical Center
    Charlottesville, Virginia 22908, United States
  • Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • VCU Clinical Research Services Unit (CRSU) [Patient Site Address]
    Richmond, Virginia 23298, United States
  • University of Washington at Harborview Medical Center
    Seattle, Washington 98104, United States
  • Liver Institute Northwest
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Sep 2021, 22 months.

Results were first posted in Jul 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2019
First posted
Aug 16, 2019
StartActual
Oct 17, 2019
Primary completionActual
Sep 2, 2021
CompletionActual
Sep 2, 2021
Results first posted
Jul 27, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04060147
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 16, 2019
Start date
Oct 17, 2019
Primary completion
Sep 2, 2021
Completion
Sep 2, 2021
Results posted
Jul 27, 2023
Last update
Jul 27, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion